Marta J. Van Beek, M.D., M.P.H., sees problems when she looks with the Merit-based Incentive Payment System (MIPS). “The ...
A compound isolated from an edible mushroom may hold the potential as an anti-cancer agent against melanoma, according to a ...
Health-related quality of life (HRQoL) in children with interstitial lung disease (ILD) is strongly influenced by clinical and developmental factors such as recent hospitalizations and poor growth, ...
Novo Nordisk has launched a subscription-based program for cash-paying patients who have been prescribed Wegovy (semaglutide). Beginning today, patients will be able to access the ...
In patients with moderate atopic dermatitis, the use of Opzelura (ruxolitinib) led to early and sustained improvements in ...
Incyte’s phase 3 STOP-HS data show that povorcitinib improved symptoms of moderate to severe hidradenitis suppurativa in most ...
Sunlight often gets a bad reputation, especially at a dermatology conference, but as experts emphasized during this morning’s ...
Clinicians should consider both cultural practices and genetic factors when diagnosing and treating pediatric skin conditions ...
Rewarding and incentivizing physicians to provide high quality care at a lower cost — who can object to that? The idea of value-based care is as attractive to dermatologists as it is to other ...
Developed by Incyte Corp., Opzelura is a topical nonsteroidal that is approved for patients 2 years of age and older with mild-to-moderate atopic dermatitis. It is a selective JAK1/JAK2 inhibitor that ...
At the 2026 American Academy of Dermatology meeting, Reid Waldman, M.D., shared data showing that Veradermics’ ...
This evening’s session at the 2026 American Academy of Dermatology Annual Meeting focused on an often-overlooked culprit in dermatology: arthropods. Titled “What’s Bugging You? Arthropods of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results